Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluate histological, virological, serological and biochemical response rates in chronic hepatitis B (CHB) patients receiving tenofovir or entecavir therapy

Trial Profile

Evaluate histological, virological, serological and biochemical response rates in chronic hepatitis B (CHB) patients receiving tenofovir or entecavir therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 May 2018

At a glance

  • Drugs Entecavir (Primary) ; Tenofovir (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 May 2018 New trial record
    • 24 Apr 2018 Results presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top